Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.

Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, McCormack P, Yu J, Huang X, Chiu YH, Chen Z, Schleeger S, Horny G, DiPetrillo K, Muller L, Hein A, Villard F, Scharenberg M, Ramage P, Hassiepen U, Côté S, DeGagne J, Krantz C, Eder J, Stoll B, Kulmatycki K, Feldman DL, Hoffmann P, Basson CT, Frost RJA, Khder Y.

Blood. 2019 Mar 28;133(13):1507-1516. doi: 10.1182/blood-2018-10-880849. Epub 2019 Jan 28.

PMID:
30692123
2.

TORC1 inhibition enhances immune function and reduces infections in the elderly.

Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaaq1564. doi: 10.1126/scitranslmed.aaq1564.

PMID:
29997249
3.

Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.

Kulmatycki KM, Langenickel T, Ng WH, Pal P, Zhou W, Lin TH, Rajman I, Chandra P, Sunkara G.

Int J Clin Pharmacol Ther. 2017 Sep;55(9):728-739. doi: 10.5414/CP202988.

PMID:
28737127
4.

Pradigastat disposition in humans: in vivo and in vitro investigations.

Upthagrove A, Chen J, Meyers CD, Kulmatycki K, Bretz A, Wang L, Peng L, Palamar S, Lin M, Majumdar T, Tran P, Einolf HJ.

Xenobiotica. 2017 Dec;47(12):1077-1089. doi: 10.1080/00498254.2016.1263405. Epub 2016 Dec 12.

PMID:
27855567
5.

The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions.

Bauer D, Soon RL, Kulmatycki K, Chen Y, Noe A, Chen J, Dosik JS, Meyers D.

Photochem Photobiol Sci. 2016 Aug 31;15(9):1155-1162. doi: 10.1039/c6pp00042h. Epub 2016 Jul 29.

PMID:
27471837
6.

Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.

Meyers CD, Noe A, Salunke A, Movva A, Kulmatycki K, Neelakantham S, Crissey A, Majumdar T, Chen J.

Clin Pharmacol Drug Dev. 2016 Nov;5(6):450-459. doi: 10.1002/cpdd.278. Epub 2016 Jul 3.

PMID:
27274009
7.
8.

Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects.

Mita S, Chitnis SD, Kulmatycki K, Salunke A, He YL, Zhou W, Suzuki H.

Int J Clin Pharmacol Ther. 2016 Apr;54(4):305-14. doi: 10.5414/CP202522.

PMID:
26932305
9.

Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.

Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumdar T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, Chen J.

Int J Clin Pharmacol Ther. 2015 May;53(5):345-55. doi: 10.5414/CP202275.

PMID:
25740267
10.

Novel orally swallowable IntelliCap(®) device to quantify regional drug absorption in human GI tract using diltiazem as model drug.

Becker D, Zhang J, Heimbach T, Penland RC, Wanke C, Shimizu J, Kulmatycki K.

AAPS PharmSciTech. 2014 Dec;15(6):1490-7. doi: 10.1208/s12249-014-0172-1. Epub 2014 Jul 15.

11.

Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.

Yamaguchi M, Saji T, Mita S, Kulmatycki K, He YL, Furihata K, Sekiguchi K.

Int J Clin Pharmacol Ther. 2013 Aug;51(8):641-51. doi: 10.5414/CP201902.

PMID:
23782587
12.

Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.

He YL, Kulmatycki K, Zhang Y, Zhou W, Reynolds C, Ligueros-Saylan M, Taylor A.

Int J Clin Pharmacol Ther. 2013 Sep;51(9):693-703. doi: 10.5414/CP201885.

PMID:
23782585
13.

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.

He YL, Foteinos G, Neelakantham S, Mattapalli D, Kulmatycki K, Forst T, Taylor A.

Diabetes Obes Metab. 2013 Dec;15(12):1111-9. doi: 10.1111/dom.12146. Epub 2013 Jul 14.

PMID:
23782529
14.
15.
16.

Disposition of loratadine in healthy volunteers.

Ramanathan R, Reyderman L, Kulmatycki K, Su AD, Alvarez N, Chowdhury SK, Alton KB, Wirth MA, Clement RP, Statkevich P, Patrick JE.

Xenobiotica. 2007 Jul;37(7):753-69.

PMID:
17620221
17.
18.

Drug disease interactions: role of inflammatory mediators in disease and variability in drug response.

Kulmatycki KM, Jamali F.

J Pharm Pharm Sci. 2005 Dec 16;8(3):602-25. Review.

20.

Therapeutic relevance of altered cytokine expression.

Kulmatycki KM, Jamali F.

Cytokine. 2001 Apr 7;14(1):1-10. Review.

PMID:
11298487
21.

Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat.

Grundy JS, Eliot LA, Kulmatycki KM, Foster RT.

Biopharm Drug Dispos. 1998 Apr;19(3):175-83.

PMID:
9570001

Supplemental Content

Loading ...
Support Center